Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Exemestane. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 known ✓ | P11511 | 18/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Exemestane SCHEMBL178041 | 1.00 | CYP19A1 (1.00) | CYP19A1KDM4EALDH1A1ABCB11NR3C1 | |
| Exemestane SCHEMBL172893 | 1.00 | CYP19A1 (1.00) | CYP19A1KDM4EALDH1A1ABCB11NR3C1 | |
| Exemestane SCHEMBL2233503 | 1.00 | CYP19A1 (1.00) | CYP19A1KDM4EALDH1A1ABCB11NR3C1 | |
| Exemestane SCHEMBL19452231 | 1.00 | CYP19A1 (1.00) | CYP19A1KDM4EALDH1A1ABCB11NR3C1 | |
| Exemestane SCHEMBL6730580 | 1.00 | CYP19A1 (1.00) | CYP19A1KDM4EALDH1A1ABCB11NR3C1 | |
| Exemestane SCHEMBL13794245 | 1.00 | CYP19A1 (1.00) | CYP19A1KDM4EALDH1A1ABCB11NR3C1 | |
| Exemestane SCHEMBL6215 | 1.00 | CYP19A1 (1.00) | CYP19A1KDM4EALDH1A1ABCB11NR3C1 | |
| Exemestane SCHEMBL172860 | 1.00 | CYP19A1 (1.00) | CYP19A1KDM4EALDH1A1ABCB11NR3C1 | |
| Exemestane SCHEMBL21698489 | 1.00 | CYP19A1 (1.00) | CYP19A1KDM4EALDH1A1ABCB11NR3C1 | |
| SCHEMBL13301017 | 0.92 | CYP19A1 (0.84) | CYP19A1KDM4EALDH1A1ABCB11NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2070943-A1 | Process for obtaining 6-Alkylidenandrost-1,4-diene-3one | Crystal Pharma, S.A. (ES) | 2009-06-17 | — | — | EP | claimed |
| EP-2556082-B1 | SUBSTITUTED ANDROST-4-ENE DIONES | UNIV EMORY (US) | 2017-02-22 | — | — | EP | disclosed |
| US-20150148321-A1 | SUBSTITUTED ANDROST-4-ENE DIONES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-05-28 | — | — | US | disclosed |
| US-8969327-B2 | Substituted androst-4-ene diones | EMORY UNIVERSITY (US) | 2015-03-03 | — | — | US | disclosed |
| US-20130157988-A1 | SUBSTITUTED ANDROST-4-ENE DIONES | EMORY UNIVERSITY (US) | 2013-06-20 | — | — | US | disclosed |
| EP-2556082-A2 | SUBSTITUTED ANDROST-4-ENE DIONES | Emory University (US) | 2013-02-13 | — | — | EP | disclosed |
| US-8288571-B2 | Process for preparing aromatiase inhibitor exemestane | CADILA HEALTHCARE LIMITED (IN) | 2012-10-16 | — | — | US | disclosed |
| WO-2010076811-A3 | PROCESS FOR THE PREPARATION OF EXEMESTANE | IND-SWIFT LABORATORIES LIMITED (IN) | 2012-06-14 | — | — | WO | disclosed |
| US-20110118488-A1 | PROCESS FOR OBTAINING 6-ALKYLIDENANDROST-1, 4-DIENE-3-ONE | CRYSTAL PHARMA, S.A. (ES) | 2011-05-19 | — | — | US | disclosed |
| US-20100311993-A1 | PROCESS FOR PREPARING AROMATIASE INHIBITOR EXEMESTANE | CADILA HEALTHCARE LIMITED (IN) | 2010-12-09 | — | — | US | disclosed |
| EP-2070943-A1 | Process for obtaining 6-Alkylidenandrost-1,4-diene-3one | Crystal Pharma, S.A. (ES) | 2009-06-17 | — | — | EP | disclosed |
| EP-1377298-B1 | EXEMESTANE FOR TREATING HORMONO-DEPENDENT DISORDERS | PFIZER ITALIA SRL (IT) | 2006-08-30 | — | — | EP | disclosed |
| EP-1435967-A2 | METHODS FOR PREVENTING AND TREATING BONE LOSS WITH STEROID COMPOUNDS | Pharmacia Italia S.p.A. (IT) | 2004-07-14 | — | — | EP | disclosed |
| US-20040082557-A1 | Methods for treating estrogen-dependent disorders | PHARMACIA ITALIA S.P.A. (IT) | 2004-04-29 | — | — | US | disclosed |
| US-20040024044-A1 | Exemestane as chemopreventing agent | PHARMACIA ITALIA S.P.A. (IT) | 2004-02-05 | — | — | US | disclosed |
| EP-1377298-A2 | COMBINED METHOD FOR TREATING HORMONO-DEPENDENT DISORDERS | Pharmacia Italia S.p.A. (IT) | 2004-01-07 | — | — | EP | disclosed |
| EP-1317270-A1 | EXEMESTANE FOR THE TREATMENT OF OESTROGEN-DEPENDENT CANCERS | Pharmacia Italia S.p.A. (IT) | 2003-06-11 | — | — | EP | disclosed |
| WO-2003032961-A2 | METHODS FOR PREVENTING AND TREATING BONE LOSS WITH STEROID COMPOUNDS | PHARMACIA ITALIA SPA (IT) | 2003-04-24 | — | — | WO | disclosed |
| WO-2002072106-A2 | COMBINED METHOD FOR TREATING HORMONO-DEPENDENT DISORDERS WITH EXEMESTANE | PHARMACIA ITALIA SPA (IT) | 2002-09-19 | — | — | WO | disclosed |
| WO-2002020020-A1 | EXEMESTANE AS CHEMOPREVENTING AGENT | PHARMACIA ITALIA S.P.A. (IT) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118488-A1 | PROCESS FOR OBTAINING 6-ALKYLIDENANDROST-1, 4-DIENE-3-ONE | SRD5A1, SRD5A2, NR5A1 | CYP19A1 6/4885KDM4E 2350/4885ALDH1A1 120/4885 |
| US-20100311993-A1 | PROCESS FOR PREPARING AROMATIASE INHIBITOR EXEMESTANE | CYP19A1, POR, CYP17A1 | CYP19A1 1/4885KDM4E 263/4885ALDH1A1 349/4885 |
| US-20130157988-A1 | SUBSTITUTED ANDROST-4-ENE DIONES | HSD17B11, AR, NR5A1 | CYP19A1 5/4885KDM4E 2222/4885ALDH1A1 756/4885 |
| US-20150148321-A1 | SUBSTITUTED ANDROST-4-ENE DIONES | HSD17B11, AR, NR5A1 | CYP19A1 5/4885KDM4E 2222/4885ALDH1A1 756/4885 |
| US-20040082557-A1 | Methods for treating estrogen-dependent disorders | CYP19A1, BRCA1, ESR2 | CYP19A1 1/4885KDM4E 738/4885ALDH1A1 630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.